2.33
2.92%
-0.07
Mersana Therapeutics Inc stock is currently priced at $2.33, with a 24-hour trading volume of 662.83K.
It has seen a -2.92% decreased in the last 24 hours and a -26.50% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.39 pivot point. If it approaches the $2.28 support level, significant changes may occur.
Previous Close:
$2.40
Open:
$2.45
24h Volume:
662.83K
Market Cap:
$285.10M
Revenue:
$36.86M
Net Income/Loss:
$-171.67M
P/E Ratio:
-1.1422
EPS:
-2.04
Net Cash Flow:
$-171.05M
1W Performance:
-2.10%
1M Performance:
-26.50%
6M Performance:
+41.21%
1Y Performance:
-69.02%
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Name
Mersana Therapeutics Inc
Sector
Industry
Phone
617-498-0020
Address
840 Memorial Drive, Cambridge
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-04-23 | Upgrade | Citigroup | Neutral → Buy |
Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
Jul-27-23 | Downgrade | BTIG Research | Buy → Neutral |
Jul-27-23 | Downgrade | Citigroup | Buy → Neutral |
Jul-27-23 | Downgrade | Guggenheim | Buy → Neutral |
Jul-27-23 | Downgrade | JP Morgan | Neutral → Underweight |
Jul-27-23 | Downgrade | Truist | Buy → Hold |
Jul-27-23 | Downgrade | Wedbush | Outperform → Neutral |
Jun-16-23 | Downgrade | JP Morgan | Overweight → Neutral |
Jun-15-23 | Initiated | Guggenheim | Buy |
Mar-16-23 | Upgrade | JP Morgan | Neutral → Overweight |
Jan-20-23 | Initiated | Citigroup | Buy |
Nov-21-22 | Initiated | Truist | Buy |
Oct-15-21 | Resumed | BTIG Research | Buy |
Aug-30-21 | Initiated | H.C. Wainwright | Buy |
Mar-31-21 | Initiated | Credit Suisse | Neutral |
Dec-03-20 | Initiated | Stifel | Buy |
Sep-29-20 | Resumed | JP Morgan | Neutral |
Apr-29-20 | Initiated | BTIG Research | Buy |
Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
Mar-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
Nov-14-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
May-08-18 | Initiated | Robert W. Baird | Outperform |
Mar-19-18 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Mersana Therapeutics Inc Stock (MRSN) Latest News
Selling Buzz: Mersana Therapeutics Inc [MRSN] Director Protopapas Anna sells 29399 shares of the company – Knox ... - Knox Daily
Knox Daily
What is the investor's view on Mersana Therapeutics Inc (MRSN)? – US Post News - US Post News
US Post News
12732 Shares in Mersana Therapeutics, Inc. (NASDAQ:MRSN) Acquired by Victory Capital Management Inc. - Defense World
Defense World
Mersana Therapeutics Inc (MRSN) can make a big difference with a little luck – Sete News - SETE News
SETE News
The Potential Rise in the Price of Mersana Therapeutics Inc (MRSN) following insiders activity – Knox Daily - Knox Daily
Knox Daily
Balance Sheet Dive: Mersana Therapeutics Inc (MRSN)'s Debt-to-Equity and Long-Term Debt/Eq Ratios – DWinneX - The Dwinnex
The Dwinnex
Mersana Therapeutics Inc Stock (MRSN) Financials Data
Mersana Therapeutics Inc (MRSN) Revenue 2024
MRSN reported a revenue (TTM) of $36.85 million for the quarter ending December 31, 2023, a +38.65% rise year-over-year.
Mersana Therapeutics Inc (MRSN) Net Income 2024
MRSN net income (TTM) was -$171.67 million for the quarter ending December 31, 2023, a +15.94% increase year-over-year.
Mersana Therapeutics Inc (MRSN) Cash Flow 2024
MRSN recorded a free cash flow (TTM) of -$171.05 million for the quarter ending December 31, 2023, a -231.75% decrease year-over-year.
Mersana Therapeutics Inc (MRSN) Earnings per Share 2024
MRSN earnings per share (TTM) was -$1.50 for the quarter ending December 31, 2023, a +31.51% growth year-over-year.
About Mersana Therapeutics Inc
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of oncology therapeutics in the United States and Canada. The company develops Dolaflexin, an antibody drug conjugate (ADC) platform designed to enhance the potency and efficacy of ADCs while simultaneously enhancing the safety and tolerability. Its lead product candidates include XMT-1522, an ADC targeting HER2-expressing tumors, which is in Phase I clinical trial for treating patients with breast cancer, non-small-cell-lung-cancer (NSCLC), and gastric cancer; and XMT-1536, an ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, NSCLC, and other cancers. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck KGaA; and Asana BioSciences, LLC. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2002 and is based in Cambridge, Massachusetts.
Cap:
|
Volume (24h):